Medtronic tests endoscopic GERD (gastroesophageal reflux disease) therapy in US trial:
This article was originally published in Clinica
Executive Summary
Medtronic has started a pivotal US trial of its endoscopic treatment for gastroesophageal reflux disease (GERD), a condition that affects 21 million Americans. The Gatekeeper reflux repair system, already approved in Europe, is designed to reduce the symptoms associated with GERD through the use of prostheses that mimic the normal functioning barrier between the stomach and the oesophagus. The US trial will include 144 patients. Importantly, Medtronic says, it is the first clinical trial of an endoscopic therapy to treat GERD that will measure the placebo effect before the product is submitted to the FDA.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.